Share:
Original Article

Reflectance confocal microscopy follow-up of multifocal superficial basal cell carcinomas treated with imiquimod 5% cream

Author Affiliation(s)

Abstract

Background Patients with multifocal superficial basal cell carcinomas (sBCC) require a non-invasive treatment and follow-up with a non-invasive technique. Imiquimod 5% cream is a new non-invasive therapy for BCC. Reflectance confocal microscopy (RCM) is a non-invasive, real-time imaging technique.


Methods:The efficacy of imiquimod 5% cream for the treatment of multifocal sBCC was evaluated, as well as the potential of RCM for assessing therapeutic effects. We reported four patients with 34 sBCC lesions were treated with imiquimod 5% cream. RCM was performed in the baseline and at 12 weeks, 24 weeks and 52 weeks after starting treatment.


Results Of 34 lesions treated with imiquimod 5%, 32 responded to the treatment and showed complete clinical clearing. Two subclinical BCC lesions were identified by RCM. The complete tumor clearance rate was 88.2%, and the efficiency rate was 97.1%. No lesion recurred at 24-month follow-up. RCM identified previously described confocal features of BCC and was more sensitive than clinical examination. Local skin reactions were relieved after expectant treatment.


Conclusions Imiquimod 5% cream may be useful for the treatment of multifocal sBCC, and its side effects are easy to manage. RCM can be used for non-invasive monitoring of treatment response and improved the tumor clearance rate.


 

Keywords : superficial basal cell carcinoma; imiquimod 5% cream; reflectance confocal microscopy;multifocal

References

1. Williams HC, Bath-Hextall F, Ozolins M, etal. Surgery Versus Imiquimod for Nodular and Superficial Basal Cell Carcinoma (SINS) Study Group. Surgery Versus 5% Imiquimod for Nodular and Superficial Basal Cell Carcinoma: 5-Year Results of the SINS Randomized Controlled Trial. J Invest Dermatol. 2017 Mar;137(3):614-619. doi: 10.1016/j.jid.2016.10.019. Epub 2016 Dec 5. PMID: 27932240. 2. Jansen MHE, Mosterd K, Arits AHMM, etal. Five-Year Results of a Randomized Controlled Trial Comparing Effectiveness of Photodynamic Therapy, Topical Imiquimod, and Topical 5-Fluorouracil in Patients with Superficial Basal Cell Carcinoma. J Invest Dermatol. 2018 Mar;138(3):527-533. doi: 10.1016/j.jid.2017.09.033. Epub 2017 Oct 16. PMID: 29045820. 3. Kadouch DJ, Schram ME, Leeflang MM, etal. In vivo confocal microscopy of basal cell carcinoma: a systematic review of diagnostic accuracy. J Eur Acad Dermatol Venereol. 2015 Oct;29(10):1890-7. doi: 10.1111/jdv.13224. Epub 2015 Aug 19. PMID: 26290493. 4. Torres A, Niemeyer A, Berkes B, etal. 5% imiquimod cream and reflectance-mode confocal microscopy as adjunct modalities to Mohs micrographic surgery for treatment of basal cell carcinoma. Dermatol Surg. 2004 Dec;30(12 Pt 1):1462-9. doi: 10.1111/j.1524-4725.2004.30504.x. PMID: 15606733. 5. Pasquali P, Segurado-Miravalles G, Freites-Martínez A, etal. Cryosurgical management of basal cell carcinoma: in vivo follow-up using reflectance confocal microscopy. Int J Dermatol. 2019 Feb;58(2):e30-e32. doi: 10.1111/ijd.14301. Epub 2018 Nov 19. PMID: 30456878. 6. Castro RP, Stephens A, Fraga-Braghiroli NA, etal. Accuracy of in vivo confocal microscopy for diagnosis of basal cell carcinoma: a comparative study between handheld and wide-probe confocal imaging. J Eur Acad Dermatol Venereol. 2015 Jun;29(6):1164-9. doi: 10.1111/jdv.12780. Epub 2014 Oct 22. PMID: 25338750. 7. Lupu M, Popa IM, Voiculescu VM, etal. A Retrospective Study of the Diagnostic Accuracy of In Vivo Reflectance Confocal Microscopy for Basal Cell Carcinoma Diagnosis and Subtyping. J Clin Med. 2019 Apr 3;8(4):449. doi: 10.3390/jcm8040449. PMID: 30987174; PMCID: PMC6518285. 8. Peccerillo F, Mandel VD, Di Tullio F, etal. Lesions Mimicking Melanoma at Dermoscopy Confirmed Basal Cell Carcinoma: Evaluation with Reflectance Confocal Microscopy. Dermatology. 2019;235(1):35-44. doi: 10.1159/000493727. Epub 2018 Nov 7. PMID: 30404078. 9. Nori S, Rius-Díaz F, Cuevas J, etal. Sensitivity and specificity of reflectance-mode confocal microscopy for in vivo diagnosis of basal cell carcinoma: a multicenter study. J Am Acad Dermatol. 2004 Dec;51(6):923-30. doi: 10.1016/j.jaad.2004.06.028. PMID: 15583584. 10. Schiessl C, Wolber C, Tauber M, etal. Treatment of all basal cell carcinoma variants including large and high-risk lesions with 5% imiquimod cream: histological and clinical changes, outcome, and follow-up. J Drugs Dermatol. 2007 May;6(5):507-13. PMID: 17679185. 11. Love WE, Bernhard JD, Bordeaux JS. Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review. Arch Dermatol. 2009 Dec;145(12):1431-8. doi: 10.1001/archdermatol.2009.291. PMID: 20026854. 12. Schulze HJ, Cribier B, Requena L, etal. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe. Br J Dermatol. 2005 May;152(5):939-47. doi: 10.1111/j.1365-2133.2005.06486.x. PMID: 15888150. 13. Shumack S, Robinson J, Kossard S, etal. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens. Arch Dermatol. 2002 Sep;138(9):1165-71. doi: 10.1001/archderm.138.9.1165. PMID: 12224977. 14. Garcia-Martin E, Gil-Arribas LM, Idoipe M, etal. Comparison of imiquimod 5% cream versus radiotherapy as treatment for eyelid basal cell carcinoma. Br J Ophthalmol. 2011 Oct;95(10):1393-6. doi: 10.1136/bjo.2010.193078. Epub 2011 Jan 17. PMID: 21242584. 15. Geisse J, Caro I, Lindholm J, etal. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol. 2004 May;50(5):722-33. doi: 10.1016/j.jaad.2003.11.066. PMID: 15097956. 16. Bostanci S, Kocyigit P, Vural S, etal. Long-Term Follow-Up Results of Topical Imiquimod Treatment in Basal Cell Carcinoma. Dermatol Surg. 2018 Jan;44(1):36-41. doi: 10.1097/DSS.0000000000001266. PMID: 29016542. 17. Geisse JK, Rich P, Pandya A, etal. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study. J Am Acad Dermatol. 2002 Sep;47(3):390-8. doi: 10.1067/mjd.2002.126215. PMID: 12196749.

Send mail to Author


Send Cancel